Belgian-Dutch compounding specialist Fagron has closed four deals in Q2—valued at €13 million—expanding its footprint in the UK, debuting in Serbia and Australia, and laying the groundwork for wider APAC growth.
Fagron kicked off the quarter by adding UK-based Active Pharma Supplies—already familiar from its earlier LSP acquisition—to its portfolio of active pharmaceutical ingredients and excipients suppliers. In Serbia, it executed a “two-for-one” entry, acquiring Uni-Chem and SB Trade to service local pharmacies and hospitals. Down under, Fagron cemented its long-standing partnership with Bella Corp, securing a foothold in Australia and marking its first entry into the APAC region.
CEO Rafael Padilla explained that after building a strong US business and investing €29 million to expand its Las Vegas facility by 2028, the company is ready to replicate that success in similar markets. “Australia mirrors the US market,” he noted, “so it’s our springboard into APAC.”
Fagron’s aggressive M&A drive complements its organic performance: H1 organic revenue rose 7.8 percent to €476 million (11.3 percent at constant FX), while recurring EBITDA climbed 12.3 percent to €95 million, lifting margins to 20 percent. For Belgian pharmacies and wholesalers, Fagron’s expanded global network promises broader access to tailored compounding solutions.
